Dr. Christenson examines the current landscape of immunotherapy in mismatch-repair proficient (pMMR) colorectal cancer, a cohort historically resistant to immune checkpoint inhibitors. The session explores the molecular rationale behind current resistance and reviews emerging strategies to sensitize pMMR tumors to immunotherapy. Through clinical data and research insights, the lecture highlights potential combination therapies and innovative approaches to improve patient outcomes in this challenging patient population.
Share it with your network and help spread clinical knowledge.
